Artificial intelligence is reshaping pharmacovigilance operations — but implementation realities vary significantly from what the market promises. For drug safety teams operating under regulatory scrutiny, the distinction between AI that is genuinely embedded into governed workflows and AI that is superficially layered onto existing systems is not a nuance. It is a risk management decision.
This webinar is designed to provide pharmacovigilance professionals with an objective, practitioner-level view of where AI is delivering measurable value in drug safety operations — and where critical gaps remain.
What This Session Covers
This 60-minute session addresses the practical realities of AI adoption in pharmacovigilance, from case processing and signal detection to regulatory reporting and team capability. Attendees will also have the opportunity to see AI-powered PV workflows demonstrated live on the Cloudbyz platform, built natively on Salesforce.
Topics include:
- How AI functions within pharmacovigilance workflows — beyond vendor positioning — and what that means for human oversight and regulatory accountability
- Why automating administrative burden is a starting point, not an endpoint, and how organisations are redirecting recovered capacity toward higher-value safety work
- How the definition of PV professional value is shifting from volume-based throughput to clinical judgement and signal interpretation
- What responsible AI adoption looks like in a regulated environment, including governance, explainability, and human-in-the-loop requirements.
